Drugs / PGT121
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03928821 | Jul 2019 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03205917 | Oct 2017 → Apr 2020 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 1 | NCT02960581 | Nov 2016 → Jul 2019 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04983030 | Apr 2022 → Feb 2026 | AIDS, acquired immunodeficiency | Boris Juelg, MD PhD | Completed | No outcome recorded |
| Phase 1/2 | NCT04144335 | Jan → Dec 2020 | AIDS | University of Minnesota | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03721510 Comparator | Dec 2018 → Oct 2021 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PGT121 | “the Broadly Neutralizing Antibodies VRC07-523LS and PGT121 Plus or Minus haNK Cells for Reduction of HIV Reservoirs” NCT04144335 ↗ |
| Action | Inhibit | “PGT121 mAb was chosen for this study because it is potent, neutralizes a wide array of HIV viruses” NCT02960581 ↗ |
| Modality | Monoclonal antibody | “PGT121 monoclonal antibody” NCT02960581 ↗ |
| Route | Intravenous | “3mg/kg administered by IV Infusion” NCT02960581 ↗ |